drug
as of 2026-07-01Zuclopenthixol
zuclopenthixol
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Birte Glenthoj
3 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
SchizophreniaDepressionPsychosomatic DisordersSchizophrenia Spectrum and Other Psychotic DisordersSchizophreniaAnxiety DisordersDepressionCognition DisordersPsychotic DisordersSchizoaffective DisordersPsychophysiologic DisordersDementiaAnxiety DisordersSchizophrenia and Disorders With Psychotic FeaturesDementia
Trials
3
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567Phase 3Terminated
KOLs & investigators
4
Stefan Leucht, ProfessorKOL score 87
Birte Glenthoj, MD, DMSc.KOL score 5
Helge Frieling, Prof., MDKOL score 5
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
company
trial
indication
indication
indication
indication
KOL
Stefan Leucht, Professor
personKOL score 87
Birte Glenthoj, MD, DMSc.
personKOL score 5
Helge Frieling, Prof., MD
personKOL score 5
Markus Dold, MD
personKOL score —